1. The effects of selective attention were studied in SI and SII cortex of a rhesus monkey trained to perform two tasks, a tactile discrimination task and a visual detection task. In the tactile task, a letter was displayed on a video screen in front of the monkey and the animal was rewarded for responding when the raised letter (6.0 mm letter height) scanning across its finger (15 mm/s) matched the letter on the screen. In the visual task, three illuminated squares were displayed on the screen, and the animal was rewarded for detecting when one of the squares dimmed. The neural responses evoked by the raised letters were recorded continuously while the animal's focus of attention was switched back and forth between the two tasks. 2. Significant differences between the discharge rates evoked by raised letters in the two tasks were observed in approximately 50% of neurons in SI cortex and 80% of neurons in SII cortex. The effects in SII cortex were divided between increased (58%) and decreased (22%) rates. In SI cortex only increased rates were observed. 3. The attentional effects were expressed not only as changes in overall neuronal activity but also as modifications of the form of the responses evoked by the letters. 4. Whether attentional effects were observed depended upon the behavioral relevance of individual letters. During brief periods in the tactile task when a behavioral response could not yield a reward (time-out and reward periods) the neuronal responses were not significantly different from the responses evoked by the same letters during the visual task.(ABSTRACT TRUNCATED AT 250 WORDS)

Four peptides--vasoactive intestinal polypeptide, substance P, somatostatin and a peptide-like avian pancreatic polypeptide--have been found in nerves of the human male genitalia using highly sensitive and specific methods of immunocytochemistry and radioimmunoassay. Five other peptides (met-enkephalin, leu-enkephalin, neurotensin, bombesin and cholecystokinin-8) were absent. Vasoactive intestinal polypeptide was the most abundant peptide, its highest concentration being in the proximal corpus cavernosum. Immunoelectron microscopy localized this peptide to large (97 +/- 20 nm), round, electron-dense granules of p-type nerve terminals. Vasoactive intestinal polypeptide-immunoreactive neuronal cell bodies were found in the prostate gland and the root of the corpus cavernosum. Substance P immunoreactive material was present in smaller concentration and was mainly localized in nerves around the corpuscular receptors of the glans penis. Somatostatin immunoreactive nerves were associated mainly with the smooth muscle of the seminal vesicle and the vas deferens. When antiserum to avian pancreatic polypeptide was applied, certain nerves were stained, particularly in the vas deferens, the prostate gland and the seminal vesicle. However, chromatography detected no pure avian pancreatic polypeptide suggesting the presence of a structurally related substance, possibly neuropeptide Y, which cross-reacts with the avian pancreatic polypeptide antiserum. Similar distributions between vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves and between avian pancreatic polypeptide-immunoreactive and adrenergic nerves were observed. A general neuronal marker, neuron-specific enolase, was used to investigate the general pattern of the organ's innervation. The abundance and distribution patterns of these peptide-immunoreactive nerves indicate that they may play important roles in the male sexual physiology.

No abstract

Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.

No abstract